Kalytera Therapeutics: improving bone marrow transplants with CBD – Health Europa
Posted: March 27, 2020 at 12:46 pm
The development of bone marrow transplantation procedures is widely considered one of the greatest victories in the war against cancer. The vast majority of bone marrow transplant recipients are patients with various forms of blood cancers, such as leukaemia, lymphoma or multiple myeloma. A real game changer, bone marrow transplantation has boosted survival rates for some blood cancers from nearly zero to over 85%.
Unfortunately, however, patients receiving bone marrow transplants are at high risk of developing Graft versus Host Disease (GvHD), a life-threatening complication that occurs when the transplanted cells from the donor the graft identify the transplant recipient the host as foreign.
This triggers an immune reaction that can wreak havoc in the transplanted patients body as it is attacked by the donated cells. This can occur from just days (in the case of acute GvHD) up to months or years (for chronic GvHD) after the haematopoietic cell transplantation (HCT) procedure has taken place.
The mortality rate of acute GvHD is very high in the case of grade 4 GvHD, it is over 90%. The overwhelmingly positive preliminary response of patients to CBD in preventing and treating GvHD shown in early trials, could be the key to significantly decreasing the incidence of this terrible condition.
Before we go on, there is a distinction to be made between a transplant rejection, which occurs when the immune system of the transplant recipient rejects the transplanted tissue, as may be the case in liver or heart transplants, and GvHD, which occurs when the while blood cells in the donors reject the recipient.
There are two types of bone marrow transplant: autologous (from the patients own stem cells) and allogeneic (stem cells from a donor). It is in the latter where GvHD may occur.
GvHD from allogeneic bone marrow transplants can manifest itself in many forms and degrees; ranging from mild, moderate or severe, to potentially fatal for the patient. Acute GvHD can cause rashes and blistering of the skin, nausea, vomiting, abdominal cramps accompanied by diarrhoea, jaundice; and may attack the lungs, liver and eyes. It is often associated with chronic illness, infections, disability, reduced quality of life, and is a major cause of morbidity and mortality following HCT.
Researchers estimate that despite aggressive preventive measures with immunosuppressive treatments, 30% to 50% of transplanted patients whose donors were fully matching siblings and 50% to 70% of patients whose donors were unrelated to them develop some level of GvHD.
Though it may sound surprising, currently there are no FDA approved therapies for either the prevention or treatment of acute GvHD.
Enter Kalytera Therapeutics, a clinical-stage pharmaceutical company aiming to develop cannabidiol (CBD) for the treatment of serious diseases. The companys drug development expertise and intellectual property portfolio put it at the forefront in the development of CBD-based medicines for a range of important unmet medical needs. Currently, its resources are being focused mainly on mitigating the effects of GvHD following bone marrow transplantation.
Kalytera Therapeutics lead programme, in which we are evaluating CBD for the prevention and treatment of GvHD, is in late-stage clinical testing. Kalytera Therapeutics have an ongoing open label Phase 2 clinical study to evaluate the pharmacokinetic profile, safety and efficacy of CBD for the prevention of acute GvHD with encouraging preliminary results; we are currently approaching the end of cohort 2. A series of Phase 1 studies requested by the FDA, such as the effect of food intake on the absorption of oral CBD, have also been completed.
At this stage, Kalytera Therapeutics are ready to plan a meeting with the FDA to discuss the possibility of starting a pivotal study later this year. Following the approval of Epidiolex for Dravet Syndrome by GW Pharma, the FDA has encouraged that Kalytera apply for a 505(b)2 regulatory pathway, which provides manufacturers of some types of drugs to apply for FDA approval without performing all the work required in a new drug application.
Kalytera Therapeutics have also received a Fast Track Designation to aid in the development and expedite review of drugs intended for serious or life-threatening disease and addressing an unmet medical need, for the companys CBD products for prevention and treatment of acute GvHD. This could accelerate the approval process for these products.
The obvious first step in attempting to prevent GvHD is to find donor cells that match the genetics of the immune system of the transplant recipient as closely as possible. But even in the ideal case of the donors being a sibling, the patient still must rely on drugs specially developed to cause immunosuppression of the donor cells, through either T-cell depletion or drugs. Treatments usually used for this include methotrexate, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil and antithymocyte globulin (ATG), as determined by each medical team and institution.
When it comes to treating GvHD, the grafts immune cell activation needs to be suppressed with medication, so that donor-host immune tolerance can be established once again. Most patients are given corticosteroids, which directly suppress the donors immune cell attack on the hosts tissues. This also raises the risk of infection and the relapse of cancer.
As of now, there are guidelines but there is no standard treatment for either prevention or treatment of acute GvHD. Only 30% to 50% of patients with moderate to severe GvHD respond to corticosteroids, leaving many at risk of fatal outcomes. Everyone in the healthcare system should be aware that more research is necessary to discover better treatment options to reduce the rates of mortality and morbidity in transplantation patients.
The programme Kalytera is now implementing is based on previous Phase 2a clinical trials, which showed outstanding preliminary results in the prevention of the disease by giving patients CBD orally. In the first study, 48 patients received CBD for seven days prior to the bone marrow transplant procedure and for 30 days thereafter, as opposed to a group of 101 historical controls who had been given the usual GvHD prophylaxis and treated in the same BMT unit by the same medical team.
Remarkably, results showed none of the 48 patients had developed acute GvHD in the 30 days of treatment with CBD. Those who developed GvHD did so within a median time of 60 days, whereas the control group of 101 historical controls began to develop acute GvHD in a median time of 20 days only (ranging from nine to 137).
In the CBD treated group, the rates of grade 2 to grade 4 acute GvHD by day 100 were 12.1%, compared with 46% in the control. The rate of severe grade 3 to grade 4 was 5%, compared to 10% in the control. Equally important is the finding that CBD was also safe and well tolerated, with no severe adverse events attributed to its consumption. This is consistent with safety data previously reported on CBD administered to humans, even with three to four times higher doses and even when taken over extended periods of time.
In light of these encouraging initial results, it was decided to test the efficacy of a prolonged treatment covering 100 days: the time window in which acute GvHD usually occurs. In a second study, 12 patients were administered CBD at the same dose starting from seven days before the bone marrow transplant procedure until 100 days post-transplantation. No safety issues were observed here either and only one noncompliant patient, representing 8% of the CBD treatment group, developed acute GvHD; compared to a 46% incidence at the same institution in the historical group of 101 patients described above. This is despite the fact that the majority of the patients (10 out of 12) received stem cells from unrelated donors, including five patients who received stem cells from non-fully matched donors, which would normally increase their chance of developing GvHD.
In a third Phase 2a study, which was performed for treatment of already sick patients, 10 patients with acute GvHD, who were refractory to standard treatment with high dose steroids (only 60% of patients respond to first line therapy with high dose steroids), were administered daily doses of CBD for up to three months. Strikingly, nine of the 10 patients enrolled in the study responded to treatment, seven of them achieving complete remission of GvHD and two more achieving a near-complete response.
These results are impressive when we take into account that the 12-month mortality rate among patients with grade 3 and grade 4 GvHD who do not respond to steroids exceeds 60% and 80%, respectively. Indeed, these preliminary results compare favourably with the results of the historical control group of 29 patients with steroid-refractory grades 3 and 4 GvHD, among which 26 patients died from GvHD and its complications.
With a median follow-up period of 13 months, six patients were still alive. Two patients died from leukaemia relapses, and two patients died from GvHD-related infectious complications. No patient deaths were determined to be associated with CBD treatment. This underlines the urgency of developing a product that can prevent and treat GvHD.
On the list of the 10 most expensive medical procedures, allogeneic BMT ranked fourth; while autologous BMT, at less than half the outrageous cost, still made it to the eighth place. Depending on the country and institution, costs range from tens of thousands to hundreds of thousands of dollars per procedure. The need and incentive to increase the rate of success are indisputable.
The life-saving ability of Kalyteras CBD products for the prevention and treatment of acute GvHD, currently classified as an orphan disease, means the company has good chances of obtaining premium pricing for a course of treatment. Over 20,000 patients suffer from acute GvHD following bone marrow transplantation in the six major markets of the US, Germany, the UK, France, Spain and Japan every year.
According to the January 2018 Market Forecast Report by DelveInsight Perspective, the potential market for a successful drug for prevention and treatment of GvHD in the seven major jurisdictions of the US, Germany, France, Italy, Spain, the UK and Japan is estimated to be over $408m in 2018; and could grow to approximately $1.3bn by 2027.
Once Kalyteras CBD products are approved by the FDA, the company believes that treating physicians would not be expected to prescribe anything other than its approved formulation of CBD (as opposed to a non-approved CBD that might be available online or from other commercial sources), especially since patients are often in isolation in the intensive care unit. It is safe to assume that neither private insurance nor government provided healthcare reimbursement would be available for non-prescription generic CBD in the jurisdictions where Kalytera intends to market its CBD product.
Conducting proper, large scale clinical trials with CBD is of utmost importance. Although in some areas CBD seems to be generally safe in the broader healthy population, it can be harmful to some groups, such as young adults, women of childbearing age, pregnant women, children, people with known heart conditions or low blood pressure, and the elderly.
Despite all the hype about the multiple health benefits of cannabis-based products trumpeted by many (though not clearly stated due to possible risks of liabilities for unsubstantiated claims), so far only one CBD-based drug has received FDA approval for the treatment of two rare and serious types of epilepsy.
Contrary to popular belief and anecdotal evidence, CBD is not a biologically inert compound. Rather, CBD has a complex pharmacokinetic and pharmacodynamic profile similar to any other medication with the potential to interact with other medications and medical conditions. CBD is metabolised in the liver by enzymes responsible for metabolising a large percentage of other drugs. When taken concomitantly, CBD may reduce or neutralise the intended action of those other medications. Kalytera has completed drug to drug interaction testing in vitro and is now planning to start testing in healthy subjects.
CBD oil can have negative side effects too, such as drowsiness, drop in blood pressure when taken in large doses, being potentially harmful for people with low blood pressure. Other problems are dizziness or light-headedness, appetite changes, diarrhoea, hormonal changes, hypokinesia and resting tremor when used for epilepsy. In psychotic disorders it has side effects too, but they are milder than on other drugs used until today. It can benefit some Parkinsons patients, but not all of them.
Kalytera has a solid, experienced leadership team and very strong intellectual property portfolio. We have three issued US and European patents covering the use of CBD in the prevention and treatment of GvHD, as well as four orphan drug designations for the treatment and prevention of GvHD in the US and Europe.
Our promising preliminary results indicate we will be able to help BMT patients and their donated bone marrow get along better. This will greatly improve patients quality of life, productivity and life expectancy by keeping them GvHD free.
Dr Sari SagivStero Biotechs+972 36176173david@sela.co.il
Please note: Kalytera Therapeutics Inc. have recently acquired Stero Biotechs.
This article will appear in the second issue ofMedical Cannabis Network which will be available to read in April 2020.
Excerpt from:
Kalytera Therapeutics: improving bone marrow transplants with CBD - Health Europa
- Bone Marrow Stem Cells [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- Stem cells in bone marrow are being used to treat EB [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- Stem cells in bone marrow are being used to treat EB [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Peripheral Artery Disease: Can Progenitor Cells Help? [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Bone Marrow Producing Insulin [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Stem Cells Reversing Endothelial Senescence [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Peripheral Artery Disease: Can Progenitor Cells Help? [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Science behind Enhancing Adult Stem Cells for wellbeing [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Bone Marrow Stem Cell Applications [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Immune Modulation by Bone Marrow Mesenchymal Stem Cells [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Expansion of Stem Cells by Valproic Acid [Last Updated On: June 27th, 2011] [Originally Added On: June 27th, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv [Last Updated On: June 27th, 2011] [Originally Added On: June 27th, 2011]
- StemLife's First Cord Blood Stem Cell Transplant Recipient [Last Updated On: June 28th, 2011] [Originally Added On: June 28th, 2011]
- Bone Marrow Differentiation to Heart? YES [Last Updated On: June 28th, 2011] [Originally Added On: June 28th, 2011]
- STEM CELLS FOR OTHER USES Interview with Sam Smith.wmv [Last Updated On: June 29th, 2011] [Originally Added On: June 29th, 2011]
- StemLife's First Cord Blood Stem Cell Transplant Recipient [Last Updated On: June 30th, 2011] [Originally Added On: June 30th, 2011]
- Bone marrow transplantation HD, ENG subtitles [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- Cord Blood and Bone Marrow Stem Cells for Liver Failure [Last Updated On: July 4th, 2011] [Originally Added On: July 4th, 2011]
- Bone Marrow Stem Cell Applications [Last Updated On: July 4th, 2011] [Originally Added On: July 4th, 2011]
- Bone Marrow Producing Insulin [Last Updated On: July 5th, 2011] [Originally Added On: July 5th, 2011]
- Bone Marrow Stem Cell Donation [Last Updated On: July 6th, 2011] [Originally Added On: July 6th, 2011]
- Adult Stem Cells May Target and Repair Heart Attack Damage [Last Updated On: July 6th, 2011] [Originally Added On: July 6th, 2011]
- Stem cells used for medical treatment [Last Updated On: July 7th, 2011] [Originally Added On: July 7th, 2011]
- Bone marrow transplantation HD, ENG subtitles [Last Updated On: July 8th, 2011] [Originally Added On: July 8th, 2011]
- Adult Stem Cells May Target and Repair Heart Attack Damage [Last Updated On: July 8th, 2011] [Originally Added On: July 8th, 2011]
- From Surgical Repair to Stem Cell Repair: A Surgeon's Journey by Leonard Smith MD, FACS [Last Updated On: July 13th, 2011] [Originally Added On: July 13th, 2011]
- STEM CELLS - Bone Marrow Stem Cells (Balzitt).flv [Last Updated On: July 14th, 2011] [Originally Added On: July 14th, 2011]
- Spirulina DLA Naturals [Last Updated On: July 15th, 2011] [Originally Added On: July 15th, 2011]
- Spirulina DLA Naturals [Last Updated On: July 16th, 2011] [Originally Added On: July 16th, 2011]
- Insidermedicine In 60 - January 6, 2011 [Last Updated On: July 16th, 2011] [Originally Added On: July 16th, 2011]
- Christian Drapeau Talk About - Adult Stem Cells and StemEnhance./StemTech [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- The potential of stem cells [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- Insidermedicine In 60 - March 11, 2011 [Last Updated On: July 20th, 2011] [Originally Added On: July 20th, 2011]
- Blind Girl get's cure you need to see to believe" [Last Updated On: July 23rd, 2011] [Originally Added On: July 23rd, 2011]
- STEM CELLS - Bone Marrow Stem Cells (Balzitt).flv [Last Updated On: July 23rd, 2011] [Originally Added On: July 23rd, 2011]
- Expansion of Stem Cells by Valproic Acid [Last Updated On: July 23rd, 2011] [Originally Added On: July 23rd, 2011]
- Blind Girl get's cure you need to see to believe" [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- LifeCell in Kalaignar Seithigal,Sun News [Last Updated On: July 26th, 2011] [Originally Added On: July 26th, 2011]
- Science behind Enhancing Adult Stem Cells for wellbeing [Last Updated On: July 27th, 2011] [Originally Added On: July 27th, 2011]
- Why treatment results vary after stem cell treatment [Last Updated On: July 27th, 2011] [Originally Added On: July 27th, 2011]
- From Surgical Repair to Stem Cell Repair: A Surgeon's Journey by Leonard Smith MD, FACS [Last Updated On: August 3rd, 2011] [Originally Added On: August 3rd, 2011]
- Insidermedicine In 60 - March 11, 2011 [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Why STEM-Enhance? [Last Updated On: August 10th, 2011] [Originally Added On: August 10th, 2011]
- Stem cells Transplatation in Completed Paralyze Dog. [Last Updated On: August 12th, 2011] [Originally Added On: August 12th, 2011]
- Stem cells Transplatation in Completed Paralyze Dog. [Last Updated On: August 15th, 2011] [Originally Added On: August 15th, 2011]
- Best natural skin care serum using stem cell technology [Last Updated On: August 19th, 2011] [Originally Added On: August 19th, 2011]
- "Bone Marrow Stem Cells" Donald Kohn [Last Updated On: August 29th, 2011] [Originally Added On: August 29th, 2011]
- The potential of stem cells [Last Updated On: August 31st, 2011] [Originally Added On: August 31st, 2011]
- Manatee man is paralyzed, but still plenty hopeful [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- Stem Cells and Bone Marrow Transplants by Dipnarine Maharaj MD PhD [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- MS Cure - Introduction to stem cell bone marrow transplant in Australia [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Bone Marrow/Stem Cell Transplantation: An Introduction, With Sonali Smith, MD [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Cancer Update: Autologus Stem Cell (Bone Marrow) Transplant [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Bone Marrow Stem Cell Transplant Live from Top US Hospital [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Adult Stem Cell Mobilization from Bone Marrow (Animation) [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Bone Marrow / Stem Cell Transplant Recovery Fund [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Bone Marrow Stem Cell Expansion by HOXB4 and p21 Knock Out [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Adult Stem Cell Mobilization from Bone Marrow (Animation) [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Bone Marrow/Stem Cell Transplant [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Bone Marrow/Stem Cell Transplant [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Macular Degeneration Improved With Stem Cells [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Stem Cell Transplant India,Bone Marrow Transplant India,Sickle Cell Anemia Treatment India [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Nurses Discuss Special Bonds With Bone Marrow and Stem Cell Transplant Patients [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Becoming a Blood Stem Cell Donor [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Bone Marrow and Stem Cell Transplant Patients Share Their Stories [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- LittleBigPlanet 2 - (WIP) Stem Cell Sackboy Bone Marrow Bugaloo [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- LittleBigPlanet 2 - Stem Cell Sackboy Quarter 4 Update (Bone Marrow Bugaloo) [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- Bone Marrow Transplant Program Continues to Grow, Make a Difference [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Can Stem Cell Prolotherapy or Bone Marrow Prolotherapy help articular cartilage defects? [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Multiple Sclerosis, Stem Cells, and Hope, Part 2 [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Bone Marrow Transplant Program Continues to Grow, Make a Difference [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- How to be an Anthony Nolan blood stem cell donor [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Stem Cells extracted from bone marrow [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Calum's stem cell donation for Anthony Nolan [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Cancer Update: Autologus Stem Cell (Bone Marrow) Transplant [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Bone Marrow - Stem Cell Prolotherapy [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Bone Marrow Stem Cell Aspiration and Re-Injection with PRP for Osteoarthritis by Dr Adelson [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Mesenchymal stem cells and marrow stromal cells---2nd--- [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Stem Cell Injections - Bone Marrow Prolotherapy - treatment for arthritis [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Chat w/ Dr. Maharaj, founder of S. FL. Bone Marrow/Stem Cell Transplant Institute [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]